
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1469952/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 655-720.	2.2	647
2	Elevated <i>Chlamydia pneumoniae</i> Antibodies, Cardiovascular Events, and Azithromycin in Male Survivors of Myocardial Infarction. Circulation, 1997, 96, 404-407.	1.6	605
3	ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. European Heart Journal, 2017, 38, ehw149.	2.2	511
4	Local coronary supersensitivity to diverse vasoconstrictive stimuli in patients with variant angina Circulation, 1986, 74, 1255-1265.	1.6	501
5	International standardization of diagnostic criteria for microvascular angina. International Journal of Cardiology, 2018, 250, 16-20.	1.7	494
6	Pathophysiology of Takotsubo Syndrome. Circulation, 2017, 135, 2426-2441.	1.6	471
7	Coronary artery spasm and vasoconstriction. The case for a distinction Circulation, 1990, 81, 1983-1991.	1.6	466
8	Cardiac syndrome X: Clinical characteristics and left ventricular function. Journal of the American College of Cardiology, 1995, 25, 807-814.	2.8	438
9	Mechanisms of angina pectoris in syndrome X. Journal of the American College of Cardiology, 1991, 17, 499-506.	2.8	398
10	Spontaneous coronary artery spasm in variant angina is caused by a local hyperreactivity to a generalized constrictor stimulus. Journal of the American College of Cardiology, 1989, 14, 1456-1463.	2.8	380
11	Effect of Intracoronary Serotonin on Coronary Vessels in Patients with Stable Angina and Patients with Variant Angina. New England Journal of Medicine, 1991, 324, 648-654.	27.0	369
12	Inflammatory cytokines in atherosclerosis: current therapeutic approaches. European Heart Journal, 2016, 37, 1723-1732.	2.2	346
13	High Prevalence of a Pathological Response to Acetylcholine Testing in Patients With Stable Angina Pectoris and Unobstructed Coronary Arteries. Journal of the American College of Cardiology, 2012, 59, 655-662.	2.8	339
14	International standardization of diagnostic criteria for vasospastic angina. European Heart Journal, 2017, 38, ehv351.	2.2	325
15	Clinical Usefulness, Angiographic Characteristics, and Safety Evaluation of Intracoronary Acetylcholine Provocation Testing Among 921 Consecutive White Patients With Unobstructed Coronary Arteries. Circulation, 2014, 129, 1723-1730.	1.6	271
16	Role of "Ischemia Modified Albumin", a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes. Emergency Medicine Journal, 2004, 21, 29-34.	1.0	257
17	Serum Levels of the Antiinflammatory Cytokine Interleukin-10 Are Decreased in Patients With Unstable Angina. Circulation, 2001, 104, 746-749.	1.6	252
18	Effect of Rosiglitazone on Common Carotid Intima-Media Thickness Progression in Coronary Artery Disease Patients Without Diabetes Mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 930-934.	2.4	246

#	Article	IF	CITATIONS
19	The Reno-Protective Effect of Hydration With Sodium Bicarbonate Plus N-Acetylcysteine in Patients Undergoing Emergency Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2007, 49, 1283-1288.	2.8	246
20	Markers of Inflammation and Rapid Coronary Artery Disease Progression in Patients With Stable Angina Pectoris. Circulation, 2004, 110, 1747-1753.	1.6	245
21	Increased uptake of 18F-fluorodeoxyglucose in postischemic myocardium of patients with exercise-induced angina Circulation, 1986, 74, 81-88.	1.6	237
22	Role of adenosine in pathogenesis of anginal pain Circulation, 1990, 81, 164-172.	1.6	230
23	Reappraisal of Ischemic Heart Disease. Circulation, 2018, 138, 1463-1480.	1.6	230
24	Interleukin-1 Receptor Antagonist Gene Polymorphism and Coronary Artery Disease. Circulation, 1999, 99, 861-866.	1.6	217
25	Ischemia Modified Albumin Is a Sensitive Marker of Myocardial Ischemia After Percutaneous Coronary Intervention. Circulation, 2003, 107, 2403-2405.	1.6	201
26	Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. European Heart Journal, 2012, 33, 857-865.	2.2	201
27	Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease – a cross-sectional study of predialysis, dialysis and kidney-transplantation patients. Atherosclerosis, 2011, 216, 446-451.	0.8	200
28	Long-term management of sustained, recurrent, symptomatic ventricular tachycardia with amiodarone Circulation, 1981, 64, 273-279.	1.6	198
29	The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. Journal of the American College of Cardiology, 2003, 42, 1757-1763.	2.8	192
30	Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. European Heart Journal, 2009, 30, 1837-1843.	2.2	191
31	Coronary microvascular dysfunction in the clinical setting: from mystery to reality. European Heart Journal, 2012, 33, 2771-2783.	2.2	191
32	Melatonin and circadian biology in human cardiovascular disease. Journal of Pineal Research, 2010, 49, no-no.	7.4	185
33	Cystatin C and Cardiovascular Risk. Clinical Chemistry, 2009, 55, 1932-1943.	3.2	184
34	Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart, 2006, 92, 113-114.	2.9	183
35	C-reactive protein elevation and disease activity in patients with coronary artery disease. European Heart Journal, 2004, 25, 401-408.	2.2	180
36	Effect of Treatment for <i>Chlamydia pneumoniae</i> and <i>Helicobacter pylori</i> on Markers of Inflammation and Cardiac Events in Patients With Acute Coronary Syndromes. Circulation, 2002, 106, 1219-1223.	1.6	178

#	Article	IF	CITATIONS
37	Pathophysiology and Management of Patients With Chest Pain and Normal Coronary Arteriograms (Cardiac Syndrome X). Circulation, 2004, 109, 568-572.	1.6	174
38	Coronary vasodilator reserve, pain perception, and sex in patients with syndrome X Circulation, 1994, 90, 50-60.	1.6	173
39	Induction of coronary artery spasm by a direct local action of ergonovine Circulation, 1987, 75, 577-582.	1.6	171
40	Absence of myocardial dysfunction during stress in patients with syndrome X. Journal of the American College of Cardiology, 1991, 18, 1463-1470.	2.8	163
41	Heat-Shock Protein 60-Reactive CD4 ⁺ CD28 ^{null} T Cells in Patients With Acute Coronary Syndromes. Circulation, 2004, 109, 1230-1235.	1.6	154
42	Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. American Heart Journal, 2006, 152, 253-262.	2.7	154
43	Epicardial Adipokines in Obesity and Coronary Artery Disease Induce Atherogenic Changes in Monocytes and Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1340-1346.	2.4	151
44	Myocardial Ischemia Caused by Distal Coronary-Artery Constriction in Stable Angina Pectoris. New England Journal of Medicine, 1990, 323, 514-520.	27.0	147
45	C-reactive protein, clinical presentation, and ischemic activity in patients with chest pain and normal coronary angiograms. Journal of the American College of Cardiology, 2003, 41, 1468-1474.	2.8	146
46	Rapid Angiographic Progression of Coronary Artery Disease in Patients With Angina Pectoris. Circulation, 1995, 92, 2058-2065.	1.6	146
47	Antiarrhythmic drugsa€ clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP).	1.7	144
48	Effects of Potassium Chloride and Potassium Bicarbonate on Endothelial Function, Cardiovascular Risk Factors, and Bone Turnover in Mild Hypertensives. Hypertension, 2010, 55, 681-688.	2.7	138
49	Inflammation and Microvascular Dysfunction in Cardiac Syndrome X Patients Without Conventional Risk Factors for Coronary Artery Disease. JACC: Cardiovascular Imaging, 2013, 6, 660-667.	5.3	137
50	Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris. European Heart Journal, 2005, 26, 457-463.	2.2	130
51	Evaluating the Quality of Research into a Single Prognostic Biomarker: A Systematic Review and Meta-analysis of 83 Studies of C-Reactive Protein in Stable Coronary Artery Disease. PLoS Medicine, 2010, 7, e1000286.	8.4	130
52	Transient myocardial ischemia during daily life in patients with syndrome X. American Journal of Cardiology, 1986, 58, 1242-1247.	1.6	129
53	Clinical Factors and Angiographic Features Associated With Premature Coronary Artery Disease. Chest, 1995, 108, 364-369.	0.8	126
54	Usefulness of the blood lymphocyte count in predicting recurrent instability and death in patients with unstable angina pectoris. American Journal of Cardiology, 2000, 86, 449-451.	1.6	125

#	Article	IF	CITATIONS
55	Markers of inflammation and multiple complex stenoses (pancoronary plaque vulnerability) in patients with non-ST segment elevation acute coronary syndromes. Heart, 2004, 90, 847-852.	2.9	122
56	Intravenous sodium nitrite in acute ST-elevation myocardial infarction: a randomized controlled trial (NIAMI). European Heart Journal, 2014, 35, 1255-1262.	2.2	121
57	Neurocognitive Function and Cerebral Emboli: Randomized Study of On-Pump Versus Off-Pump Coronary Artery Bypass Surgery. Annals of Thoracic Surgery, 2007, 83, 475-482.	1.3	120
58	Effects of angiotensin-converting enzyme inhibition on exercise-induced angina and ST segment depression in patients with microvascular angina. Journal of the American College of Cardiology, 1994, 23, 652-657.	2.8	118
59	The Role of Neopterin in Atherogenesis and Cardiovascular Risk Assessment. Current Medicinal Chemistry, 2009, 16, 4644-4653.	2.4	115
60	Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 180-188.	3.0	113
61	Syndrome X in women is associated with oestrogen deficiency. European Heart Journal, 1995, 16, 610-614.	2.2	111
62	Serum neopterin and complex stenosis morphology in patients with unstable angina. Journal of the American College of Cardiology, 2000, 35, 956-962.	2.8	111
63	The hyperventilation test as a method for developing successful therapy in Prinzmetal's angina. American Journal of Cardiology, 1982, 49, 834-841.	1.6	110
64	Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. European Heart Journal, 2016, 37, 1015-1023.	2.2	109
65	The parallel tales of microvascular angina and heart failure with preserved ejection fraction: a paradigm shift. European Heart Journal, 2017, 38, ehw461.	2.2	106
66	lschemia Modified Albumin for the assessment of patients presenting to the emergency department with acute chest pain but normal or non-diagnostic 12-lead electrocardiograms and negative cardiac troponin T. International Journal of Cardiology, 2004, 97, 297-301.	1.7	105
67	Concentration of circulating plasma endothelin in patients with angina and normal coronary angiograms Heart, 1995, 74, 620-624.	2.9	104
68	Total Cholesterol Content of Erythrocyte Membranes Is Increased in Patients With Acute Coronary Syndrome. Journal of the American College of Cardiology, 2007, 49, 2081-2089.	2.8	103
69	CD4+CD28null T cells in coronary artery disease: when helpers become killers. Cardiovascular Research, 2009, 81, 11-19.	3.8	101
70	High Levels of Costimulatory Receptors OX40 and 4-1BB Characterize CD4 ⁺ CD28 ^{null} T Cells in Patients With Acute Coronary Syndrome. Circulation Research, 2012, 110, 857-869.	4.5	101
71	Vitamin D deficiency and endothelial dysfunction in non-dialysis chronic kidney disease patients. Atherosclerosis, 2012, 220, 265-268.	0.8	101
72	Ischemia-Modified Albumin Concentrations in Patients with Peripheral Vascular Disease and Exercise-Induced Skeletal Muscle Ischemia. Clinical Chemistry, 2004, 50, 1656-1660.	3.2	99

#	Article	IF	CITATIONS
73	Pain threshold and tolerance in women with syndrome X and women with stable angina pectoris. American Journal of Cardiology, 1987, 60, 503-507.	1.6	98
74	Comparison of regional myocardial blood flow in syndrome X and one-vessel coronary artery disease. American Journal of Cardiology, 1993, 72, 134-139.	1.6	97
75	Coronary microvascular dysfunction in chronic inflammatory rheumatoid diseases. European Heart Journal, 2016, 37, 1799-1806.	2.2	97
76	Mixed angina pectoris. American Journal of Cardiology, 1985, 56, E30-E33.	1.6	96
77	Abnormal autonomic control of the cardiovascular system in syndrome X. American Journal of Cardiology, 1994, 73, 1174-1179.	1.6	95
78	Low dose imipramine improves chest pain but not quality of life in patients with angina and normal coronary angiograms. European Heart Journal, 1998, 19, 250-254.	2.2	95
79	A review of methods for assessment of coronary microvascular disease in both clinical and experimental settings. Cardiovascular Research, 2008, 80, 165-174.	3.8	94
80	Impact of Vitamin D Supplementation on Arterial Vasomotion, Stiffness and Endothelial Biomarkers in Chronic Kidney Disease Patients. PLoS ONE, 2014, 9, e91363.	2.5	91
81	Pregnancy-Associated Plasma Protein A and Its Endogenous Inhibitor, the Proform of Eosinophil Major Basic Protein (proMBP), Are Related to Complex Stenosis Morphology in Patients With Stable Angina Pectoris. Circulation, 2004, 109, 1724-1728.	1.6	89
82	Elevated endothelin concentrations are associated with reduced coronary vasomotor responses in patients with chest pain and normal coronary arteriograms. Journal of the American College of Cardiology, 1999, 34, 455-460.	2.8	85
83	Mechanisms and diagnostic evaluation of persistent or recurrent angina following percutaneous coronary revascularization. European Heart Journal, 2019, 40, 2455-2462.	2.2	85
84	Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group. European Heart Journal, 2021, 42, 4592-4600.	2.2	84
85	Angiographic Stenosis Progression and Coronary Events in Patients With â€ ⁻ Stabilized' Unstable Angina. Circulation, 1995, 91, 2319-2324.	1.6	84
86	Serum neopterin in acute coronary syndromes. Lancet, The, 1997, 349, 1252-1253.	13.7	83
87	Relationship among pregnancy associated plasma protein-A levels, clinical characteristics, and coronary artery disease extent in patients with chronic stable angina pectoris. European Heart Journal, 2005, 26, 2093-2098.	2.2	83
88	Effect of Azithromycin Treatment on Endothelial Function in Patients With Coronary Artery Disease and Evidence ofChlamydia pneumoniaeInfection. Circulation, 2002, 105, 1298-1303.	1.6	77
89	Rarefaction of skin capillaries in patients with anginal chest pain and normal coronary arteriograms. European Heart Journal, 2001, 22, 1144-1148.	2.2	75
90	Multiple complex stenoses, high neutrophil count and C-reactive protein levels in patients with chronic stable angina. Atherosclerosis, 2004, 175, 151-157.	0.8	74

#	Article	IF	CITATIONS
91	Atherosclerosis and Oxidant Stress: The End of the Road for Antioxidant Vitamin Treatment?. Cardiovascular Drugs and Therapy, 2007, 21, 195-210.	2.6	74
92	Relation of ischemia-modified albumin (IMA) levels following elective angioplasty for stable angina pectoris to duration of balloon-induced myocardial ischemia. American Journal of Cardiology, 2003, 92, 322-324.	1.6	73
93	Smallâ€Vessel Disease in the Heart and Brain: Current Knowledge, Unmet Therapeutic Need, and Future Directions. Journal of the American Heart Association, 2019, 8, e011104.	3.7	71
94	Chronic inflammation and increased arterial stiffness in patients with cardiac syndrome X. European Heart Journal, 2003, 24, 2006-2011.	2.2	70
95	Vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 serum level in patients with chest pain and normal coronary arteries (syndrome X). Clinical Cardiology, 2001, 24, 301-304.	1.8	69
96	Vasodilator Therapy: Nitrates and Nicorandil. Cardiovascular Drugs and Therapy, 2016, 30, 367-378.	2.6	69
97	Provocation of coronary spasm by dopamine in patients with active variant angina pectoris Circulation, 1986, 74, 262-269.	1.6	68
98	Peroxisome proliferator-activated receptor-Î ³ agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease. American Heart Journal, 2004, 147, 1032-1037.	2.7	68
99	Takotsubo Syndrome (Stress Cardiomyopathy): An Intriguing Clinical Condition in Search of Its Identity. American Journal of Medicine, 2014, 127, 699-704.	1.5	66
100	Chest pain during daily life in patients with hypertrophic cardiomyopathy: an ambulatory electrocardiographic study. European Heart Journal, 1996, 17, 1056-1064.	2.2	65
101	Inflammatory and anti-inflammatory variable clusters and risk prediction in acute coronary syndrome patients: A factor analysis approach. Atherosclerosis, 2007, 193, 196-203.	0.8	64
102	Cardiac Syndrome X. American Journal of Cardiovascular Drugs, 2004, 4, 179-194.	2.2	63
103	Therapeutic options for the management ofpatients with cardiac syndrome X. European Heart Journal, 2001, 22, 283-293.	2.2	62
104	Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus**The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of this report American Journal of Cardiology, 2004, 94, 151-156.	1.6	62
105	Cardiac syndrome X in women: the role of oestrogen deficiency. Heart, 2006, 92, iii5-iii9.	2.9	62
106	Increased serum neopterin: a marker of coronary artery disease activity in women. British Heart Journal, 2000, 83, 346-350.	2.1	61
107	Overview of gender aspects of cardiac syndrome X. Cardiovascular Research, 2002, 53, 620-626.	3.8	61
108	Lack of evidence for alpha-adrenergic receptor-mediated mechanisms in the genesis of ischemia in syndrome X. American Journal of Cardiology, 1989, 64, 264-269.	1.6	60

#	Article	IF	CITATIONS
109	Differential plasma endothelin levels in subgroups of patients with angina and angiographically normal coronary arteries. American Heart Journal, 1998, 136, 412-417.	2.7	60
110	Different susceptibility to myocardial ischemia provoked by hyperventilation and cold pressor test in exertional and variant angina pectoris. American Journal of Cardiology, 1985, 56, 18-22.	1.6	58
111	Efficacy of carvedilol (BM14, 190), a new beta-blocking drug with vasodilating properties, in exercise-induced ischemia. American Journal of Cardiology, 1985, 56, 35-40.	1.6	58
112	Elevated Plasma Lipoprotein(a) Is Associated With Coronary Artery Disease in Patients With Chronic Stable Angina Pectoris 11Dr. Cox is supported by a Fellowship Grant from the British Heart Foundation, London Journal of the American College of Cardiology, 1998, 31, 1260-1266.	2.8	57
113	Failure to demonstrate myocardial ischaemia in patients with angina and normal coronary arteries. Evaluation by continuous coronary sinus pH monitoring and lactate metabolism. European Heart Journal, 1996, 17, 1175-1180.	2.2	56
114	Dipyridamole stress thallium-201 perfusion abnormalities in patients with hypertrophic cardiomyopathy. Relationship to clinical presentation and outcome. European Heart Journal, 1998, 19, 500-507.	2.2	56
115	Prognostic value of neopterin levels in treated patients with hypertension and chest pain but without obstructive coronary artery disease. American Journal of Cardiology, 2004, 93, 627-629.	1.6	55
116	Plasma cystatin C for prediction of 1-year cardiac events in Mediterranean patients with non-ST elevation acute coronary syndrome. Atherosclerosis, 2010, 209, 300-305.	0.8	55
117	C-reactive protein in patients with chronic stable angina: differences in baseline serum concentration between women and men. European Heart Journal, 2000, 21, 1598-1606.	2.2	54
118	Safety of intracoronary provocative testing for the diagnosis of coronary artery spasm. International Journal of Cardiology, 2017, 244, 77-83.	1.7	53
119	Variant angina pectoris. Role of coronary spasm in the development of fixed coronary obstructions Circulation, 1992, 85, 619-626.	1.6	52
120	Heart rate response during exercise testing and ambulatory ECG monitoring in patients with syndrome X. American Heart Journal, 1991, 122, 458-463.	2.7	51
121	Comparison of ischemia-modified albumin levels in patients undergoing percutaneous coronary intervention for unstable angina pectoris with versus without coronary collaterals. American Journal of Cardiology, 2004, 93, 88-90.	1.6	51
122	Pregnancy-associated plasma protein-A (PAPP-A) and cardiovascular risk. Atherosclerosis, 2009, 203, 346-352.	0.8	51
123	Interleukin-18: Interleukin-10 ratio and in-hospital adverse events in patients with acute coronary syndrome. Atherosclerosis, 2005, 182, 135-143.	0.8	50
124	Mean platelet volume predicts patency of the infarct-related artery before mechanical reperfusion and short-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Thrombosis Research, 2009, 124, 536-540.	1.7	50
125	Inflammatory Mechanisms in COVID-19 and Atherosclerosis: Current Pharmaceutical Perspectives. International Journal of Molecular Sciences, 2021, 22, 6607.	4.1	50
126	Improved coronary supply: Prevailing mechanism of action of nitrates in chronic stable angina. American Heart Journal, 1985, 110, 238-245.	2.7	49

#	Article	IF	CITATIONS
127	Angina pectoris and normal coronary arteriograms: Clinical presentation and hemodynamic characteristics. American Journal of Cardiology, 1995, 76, 35D-42D.	1.6	49
128	Predictive value of coronary artery stenoses and C-reactive protein levels in patients with stable coronary artery disease. Atherosclerosis, 2009, 204, 239-243.	0.8	49
129	Inflammatory Systemic Biomarkers in Setting Acute Coronary Syndromes - Effects of the Diurnal Variation. Current Drug Targets, 2009, 10, 1001-1008.	2.1	49
130	Decreased levels of alternative co-stimulatory receptors OX40 and 4-1BB characterise T cells from head and neck cancer patients. Immunobiology, 2012, 217, 669-675.	1.9	49
131	Increased coronary vasoconstrictor response to acetylcholine in women with chest pain and normal coronary arteriograms (cardiac syndrome X). Clinical Research in Cardiology, 2012, 101, 673-681.	3.3	49
132	Women-specific predictors of cardiovascular disease risk - new paradigms. International Journal of Cardiology, 2019, 286, 190-197.	1.7	49
133	Risk factors profile of young and older patients with myocardial infarction. Cardiovascular Research, 2022, 118, 2281-2292.	3.8	49
134	Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management—a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. European Heart Journal, 2017, 38, ehv676.	2.2	48
135	High plasma immunoreactive endothelin levels in patients with Chagas' cardiomyopathy. American Journal of Cardiology, 2001, 87, 1217-1220.	1.6	47
136	A comparative study of biomarkers for risk prediction in acute coronary syndrome—Results of the SIESTA (Systemic Inflammation Evaluation in non-ST-elevation Acute coronary syndrome) study. Atherosclerosis, 2010, 212, 636-643.	0.8	47
137	Optimism and Recovery After Acute Coronary Syndrome. Psychosomatic Medicine, 2015, 77, 311-318.	2.0	47
138	Relation of Circulating C-Reactive Protein to Progression of Aortic Valve Stenosis. American Journal of Cardiology, 2006, 97, 90-93.	1.6	46
139	The pathogenic role of coronary microvascular dysfunction in the setting of other cardiac or systemic conditions. Cardiovascular Research, 2020, 116, 817-828.	3.8	46
140	Epicardial coronary artery tone and reactivity in patients with normal coronary arteriograms and reduced coronary flow reserve (syndrome X). Journal of the American College of Cardiology, 1991, 18, 50-54.	2.8	45
141	Effect of direct-current cardioversion on ischemia- modified albumin levels in patients with atrial fibrillation. American Journal of Cardiology, 2004, 93, 366-368.	1.6	45
142	Elevated serum neopterin levels and adverse cardiac events at 6 months follow-up in Mediterranean patients with non-ST-segment elevation acute coronary syndrome. Atherosclerosis, 2008, 201, 176-183.	0.8	45
143	Differential progression of complex and smooth stenoses within the same coronary tree in men with stable coronary artery disease. Journal of the American College of Cardiology, 1995, 25, 837-842.	2.8	44
144	Plasma immunoreactive endothelin concentration correlates with severity of coronary artery disease in patients with stable angina pectoris and normal ventricular function. Journal of the American College of Cardiology, 1996, 28, 14-19.	2.8	44

#	Article	IF	CITATIONS
145	Interleukin-18/interleukin-10 ratio is an independent predictor of recurrent coronary events during a 1-year follow-up in patients with acute coronary syndrome. International Journal of Cardiology, 2007, 117, 333-339.	1.7	44
146	Association of ischemia-modified albumin and melatonin in patients with ST-elevation myocardial infarction. Atherosclerosis, 2008, 199, 73-78.	0.8	44
147	Implications of geographical variation on clinical outcomes of cardiovascular trials. American Heart Journal, 2012, 164, 303-312.	2.7	44
148	Pharmacological treatment of chronic stable angina pectoris. Clinical Medicine, 2013, 13, 63-70.	1.9	44
149	Relation between stimulation site of cardiac afferent nerves by adenosine and distribution of cardiac pain: Results of a study in patients with stable angina. Journal of the American College of Cardiology, 1992, 20, 1498-1502.	2.8	43
150	Heart rate variability depression in patients with unstable angina. American Heart Journal, 1995, 130, 772-779.	2.7	42
151	Assessment of quality of life in patients with chest pain and normal coronary arteriogram (syndrome) Tj ETQq1 2	l 0.784314 1.8	rgBT /Oved
152	Inflammation and symptoms of depression and anxiety in patients with acute coronary heart disease. Brain, Behavior, and Immunity, 2013, 31, 183-188.	4.1	42
153	Comparison of epicardial coronary artery tone and reactivity in Prinzmetal's variant angina and chronic stable angina pectoris. Journal of the American College of Cardiology, 1991, 17, 1058-1062.	2.8	41
154	Increased plasma endothelin levels in angina patients with rapid coronary artery disease progression. European Heart Journal, 2001, 22, 1578-1584.	2.2	41
155	Apolipoprotein E Genotype and Circulating Interleukin-10 Levels in Patients With Stable and Unstable Coronary Artery Disease. Journal of the American College of Cardiology, 2006, 48, 2471-2481.	2.8	41
156	Insulin Resistance, Inflammation, and Vascular Disease in Nondiabetic Predialysis Chronic Kidney Disease Patients. Clinical Cardiology, 2011, 34, 360-365.	1.8	41
157	Proteasome-Mediated Reduction in Proapoptotic Molecule Bim Renders CD4 ⁺ CD28 ^{null} T Cells Resistant to Apoptosis in Acute Coronary Syndrome. Circulation, 2015, 131, 709-720.	1.6	41
158	Myocardial ischemia during ergonovine testing: different susceptibility to coronary vasoconstriction in patients with exertional and variant angina Circulation, 1984, 69, 690-695.	1.6	40
159	S100 protein and its relation to cerebral microemboli in on-pump and off-pump coronary artery bypass surgery. European Journal of Cardio-thoracic Surgery, 2004, 25, 409-414.	1.4	40
160	New Universal Definition of Myocardial Infarction. JACC: Cardiovascular Interventions, 2010, 3, 950-958.	2.9	40
161	Comprehensive efforts to increase adherence to statin therapy. European Heart Journal, 2017, 38, ehw628.	2.2	40
162	Predictors of poor clinical outcomes in patients with acute myocardial infarction and non-obstructed coronary arteries (MINOCA). International Journal of Cardiology, 2018, 267, 41-45.	1.7	40

#	Article	IF	CITATIONS
163	Validation of a New Risk Score to Predict Contrast-Induced Nephropathy After Percutaneous Coronary Intervention. American Journal of Cardiology, 2014, 113, 1487-1493.	1.6	39
164	Nordic walking for individuals with cardiovascular disease: A systematic review and meta-analysis of randomized controlled trials. European Journal of Preventive Cardiology, 2017, 24, 1938-1955.	1.8	38
165	Mechanisms and significance of cardiac ischemic pain. Progress in Cardiovascular Diseases, 1992, 35, 1-18.	3.1	37
166	Effects of transcendental meditation on symptoms and electrocardiographic changes in patients with cardiac syndrome X. American Journal of Cardiology, 2000, 85, 653-655.	1.6	37
167	Pharmacological therapy for the prevention of cardiovascular events in patients with myocardial infarction with non-obstructed coronary arteries (MINOCA): Insights from a multicentre national registry. International Journal of Cardiology, 2021, 327, 9-14.	1.7	37
168	Coronary vasomotor effects of serotonin in patients with angina. Relation to coronary stenosis morphology Circulation, 1993, 88, 1518-1526.	1.6	36
169	Interleukin-8 is increased in the membrane of circulating erythrocytes in patients with acute coronary syndrome. European Heart Journal, 2008, 29, 2713-2722.	2.2	36
170	Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention—Effects on soluble CD40 ligand concentrations. Atherosclerosis, 2009, 206, 523-527.	0.8	36
171	Nicorandil and Long-acting Nitrates: Vasodilator Therapies for the Management of Chronic Stable Angina Pectoris. European Cardiology Review, 2018, 13, 23.	2.2	36
172	Effect of α1-Adrenoceptor Blockade on Coronary Vasodilator Reserve in Cardiac Syndrome X. Journal of Cardiovascular Pharmacology, 1999, 34, 554-560.	1.9	36
173	Rapid angiographic progression of "target―and "nontarget―stenoses in patients awaiting coronary angioplasty. Journal of the American College of Cardiology, 1995, 26, 416-421.	2.8	35
174	Biochemical and bioimaging markers for risk assessment and diagnosis in major cardiovascular diseases: a road to integration of complementary diagnostic tools. Journal of Internal Medicine, 2007, 261, 214-234.	6.0	35
175	Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 108-118.	3.0	35
176	Reactivity of eccentric and concentric coronary stenoses in patients with chronic stable angina. Journal of the American College of Cardiology, 1991, 17, 627-633.	2.8	34
177	Light/dark patterns of soluble vascular cell adhesion molecule-1 in relation to melatonin in patients with ST-segment elevation myocardial infarction. Journal of Pineal Research, 2007, 44, 071018055808002-???.	7.4	33
178	Fear of dying and inflammation following acute coronary syndrome. European Heart Journal, 2011, 32, 2405-2411.	2.2	33
179	Refractory variant angina relieved by guanethidine and clonidine. American Journal of Cardiology, 1988, 62, 832-833.	1.6	32
180	Regional Variations in Endothelin-1 and its Receptor Subtypes in Human Coronary Vasculature: Pathophysiological Implications in Coronary Disease. Endothelium: Journal of Endothelial Cell Research, 1998, 6, 61-70.	1.7	32

#	Article	IF	CITATIONS
181	Prognostic Value of Admission Myeloperoxidase Levels in Patients With ST-Segment Elevation Myocardial Infarction and Cardiogenic Shock. American Journal of Cardiology, 2008, 101, 1537-1540.	1.6	32
182	Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation. Current Medical Research and Opinion, 2011, 27, 141-150.	1.9	32
183	Variability of coronary blood flow reserve assessed by Doppler catheter after successful thrombolysis in patients with acute myocardial infarction. American Heart Journal, 1993, 125, 1547-1552.	2.7	31
184	Brachial Artery Flow-Mediated Dilation and Myocardial Perfusion in Patients With Cardiac Syndrome X. American Journal of Cardiology, 2005, 95, 1478-1480.	1.6	31
185	Differential Pathways Govern CD4+CD28â^'T Cell Proinflammatory and Effector Responses in Patients with Coronary Artery Disease. Journal of Immunology, 2008, 181, 5233-5241.	0.8	31
186	Coronary microvascular spasm triggers transient ischemic left ventricular diastolic abnormalities in patients with chest pain and angiographically normal coronary arteries. Atherosclerosis, 2014, 236, 207-214.	0.8	31
187	Increased QT dispersion in patients with Prinzmetal's variant angina and cardiac arrest. Cardiovascular Research, 2001, 50, 379-385.	3.8	30
188	lschemia-modified albumin predicts short-term outcome and 1-year mortality in patients attending the emergency department for acute ischemic chest pain. Heart and Vessels, 2008, 23, 174-180.	1.2	30
189	Cardiovascular effects of medroxyprogesterone acetate and progesterone: a case of mistaken identity?. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 387-395.	3.3	30
190	Usefulness of holter monitoring to improve the sensitivity of exercise testing in determining the degree of myocardial revascularization after coronary artery bypass grafting for stable angina pectoris. American Journal of Cardiology, 1987, 60, 40-43.	1.6	29
191	Peroxisome Proliferator-Activated Receptor-?? Agonists for Management and Prevention of Vascular Disease in Patients with and without Diabetes Mellitus. American Journal of Cardiovascular Drugs, 2006, 6, 231-242.	2.2	29
192	Prognostic value of circulating pregnancy-associated plasma protein-A (PAPP-A) and proform of eosinophil major basic protein (pro-MBP) levels in patients with chronic stable angina pectoris. Clinica Chimica Acta, 2008, 391, 18-23.	1.1	29
193	Efficacy of amiodarone during long-term treatment of potentially dangerous ventricular arrhythmias in patients with chronic stable ischemic heart disease. American Heart Journal, 1984, 107, 648-655.	2.7	28
194	Management of vasospastic angina?Role of nicorandil. Cardiovascular Drugs and Therapy, 1995, 9, 221-227.	2.6	28
195	Transient autonomic dysfunction precedes ST-segment depression in patients with syndrome X. American Journal of Cardiology, 1996, 77, 942-947.	1.6	28
196	Neointimal Hyperplasia and Calcification in Medium Sized Arteries in Adult Patients with Chronic Kidney Disease. Seminars in Dialysis, 2015, 28, E35-40.	1.3	28
197	Pulse pressure and progression of chronic kidney disease. Journal of Nephrology, 2010, 23, 189-93.	2.0	28
198	Long-term variability of angina pectoris and electrocardiographic signs of ischemia in syndrome X. American Journal of Cardiology, 1989, 64, 139-143.	1.6	27

#	Article	IF	CITATIONS
199	Similar time course of ST depression during and after exercise in patients with coronary artery disease and syndrome X. American Heart Journal, 1990, 120, 848-854.	2.7	27
200	Creatine kinase MB isoforms: sensitive markers of ischemic myocardial damage. Clinical Chemistry, 1994, 40, 1265-1271.	3.2	27
201	CD14 C(-260)T promoter polymorphism and prevalence of acute coronary syndromes. International Journal of Cardiology, 2005, 98, 307-312.	1.7	27
202	Evaluation of ASPIRE trial: a Phase III pivotal registration trial, using intracoronary administration of Generx (Ad5FGF4) to treat patients with recurrent angina pectoris. Expert Opinion on Biological Therapy, 2013, 13, 1749-1753.	3.1	27
203	Targeting T cells to treat atherosclerosis: odyssey from bench to bedside. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 194-199.	3.0	27
204	Effect of radiofrequency catheter ablation on the biochemical marker ischemia modified albumin. American Journal of Cardiology, 2004, 94, 234-236.	1.6	26
205	Soluble CD40 ligand:interleukin-10 ratio predicts in-hospital adverse events in patients with ST-segment elevation myocardial infarction. Thrombosis Research, 2007, 121, 293-299.	1.7	26
206	Independent and additive predictive value of total cholesterol content of erythrocyte membranes with regard to coronary artery disease clinical presentation. International Journal of Cardiology, 2011, 150, 22-27.	1.7	26
207	Statin pretreatment and risk of in-hospital atrial fibrillation among patients undergoing cardiac surgery: a collaborative meta-analysis of 11 randomized controlled trials. Europace, 2015, 17, 855-863.	1.7	26
208	Abnormal uptake and washout of thallium-201 in patients with syndrome X and normal-appearing scans. American Journal of Cardiology, 1995, 75, 400-402.	1.6	25
209	A comparative study of markers of inflammation for the assessment of cardiovascular risk in patients presenting to the emergency department with acute chest pain suggestive of acute coronary syndrome. International Journal of Cardiology, 2006, 109, 317-321.	1.7	25
210	Obesity, Inflammation and Brachial Artery Flow-Mediated Dilatation: Therapeutic Targets in Patients with Microvascular Angina (Cardiac Syndrome X). Cardiovascular Drugs and Therapy, 2012, 26, 239-244.	2.6	25
211	Emotional triggering and low socio-economic status as determinants of depression following acute coronary syndrome. Psychological Medicine, 2011, 41, 1857-1866.	4.5	24
212	Anaemia and the development of depressive symptoms following acute coronary syndrome: longitudinal clinical observational study. BMJ Open, 2012, 2, e000551.	1.9	24
213	Impact of p16 status on pro- and anti-angiogenesis factors in head and neck cancers. British Journal of Cancer, 2015, 113, 653-659.	6.4	24
214	TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2. Frontiers in Immunology, 2019, 10, 1644.	4.8	24
215	Clinical characteristics and long-term prognosis of contemporary patients with vasospastic angina. International Journal of Cardiology, 2019, 291, 13-18.	1.7	24
216	Variability of results during repeat exercise stress testing in patients with stable angina pectoris: Role of dynamic coronary flow reserve. American Heart Journal, 1986, 112, 249-254.	2.7	23

#	Article	IF	CITATIONS
217	Prognostic value of corrected QT-interval prolongation in patients with unstable angina pectoris. American Journal of Cardiology, 2003, 92, 203-205.	1.6	23
218	Antioxidant treatment for heart failure: friend or foe?. QJM - Monthly Journal of the Association of Physicians, 2009, 102, 305-310.	0.5	23
219	The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 85-99.	3.0	23
220	Myocardial beta-adrenoceptor density and plasma catecholamines in syndrome X. American Journal of Cardiology, 1996, 78, 37-42.	1.6	22
221	Neopterin: Still a Forgotten Biomarker. Clinical Chemistry, 2005, 51, 1902-1903.	3.2	22
222	Health-Related Quality of Life Outcome After On-Pump Versus Off-Pump Coronary Artery Bypass Graft Surgery: A Prospective Randomized Study. Annals of Thoracic Surgery, 2006, 82, 615-619.	1.3	22
223	Diurnal variation of soluble CD40 ligand in patients with acute coronary syndrome. Soluble CD40 ligand and diurnal variation. Thrombosis Research, 2009, 123, 617-621.	1.7	22
224	The Role of Microbiota in Cardiovascular Risk: Focus on Trimethylamine Oxide. Current Problems in Cardiology, 2019, 44, 182-196.	2.4	22
225	Cardiac and vascular changes with kidney transplantation. Indian Journal of Nephrology, 2016, 26, 1.	0.5	22
226	Reactivity of proximal and distal angiographically normal and stenotic coronary segments in chronic stable angina pectoris. American Journal of Cardiology, 1991, 67, 1195-1200.	1.6	21
227	Effects of aminophylline on cardiac function and regional myocardial perfusion: Implications regarding its antiischemic action. American Heart Journal, 1994, 127, 817-824.	2.7	21
228	Chest pain and normal coronary arteriograms: role of "microvascular spasm― Lancet, The, 1998, 351, 1144-1145.	13.7	21
229	Prevention of Coronary Hyperreactivity in Preatherogenic Menopausal Rhesus Monkeys by Transdermal Progesterone. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 955-961.	2.4	21
230	Levosimendan Use Reduces Matrix Metalloproteinase-2 in Patients with Decompensated Heart Failure. Cardiovascular Drugs and Therapy, 2005, 19, 399-402.	2.6	21
231	High serum matrix metalloproteinase-9 level predict increased risk of in-hospital cardiac events in patients with type 2 diabetes and ST segment elevation myocardial infarction. Atherosclerosis, 2008, 196, 365-371.	0.8	21
232	Statin Use is Associated with a Significant Reduction in Cholesterol Content of Erythrocyte Membranes. A Novel Pleiotropic Effect?. Cardiovascular Drugs and Therapy, 2009, 23, 471-480.	2.6	21
233	Neopterin levels and left ventricular dysfunction in patients with chronic stable angina pectoris. Atherosclerosis, 2009, 207, 514-518.	0.8	21
234	Anti-inflammatory effects of ivabradine in patients with acute coronary syndrome: a pilot study. International Journal of Cardiology, 2012, 158, 160-162.	1.7	21

#	Article	IF	CITATIONS
235	Effects of neuropeptide Y on coronary artery vasomotion in patients with microvascular angina. International Journal of Cardiology, 2017, 238, 123-127.	1.7	21
236	Truncated human endothelin receptor A produced by alternative splicing and its expression in melanoma. British Journal of Cancer, 1998, 78, 1141-1146.	6.4	20
237	Management of Tako-tsubo Syndrome. Cardiovascular Drugs and Therapy, 2008, 22, 71-77.	2.6	20
238	Neopterin and Cardiovascular Disease: Growing Evidence for a Role in Patient Risk Stratification. Clinical Chemistry, 2009, 55, 1056-1057.	3.2	20
239	Individualized cardiovascular risk assessment by cardiovascular magnetic resonance. Future Cardiology, 2014, 10, 273-289.	1.2	20
240	Interleukin-7 and interleukin-15 drive CD4+CD28null T lymphocyte expansion and function in patients with acute coronary syndrome. Cardiovascular Research, 2021, 117, 1935-1948.	3.8	20
241	Angiotensin-converting enzyme insertion/deletion polymorphism and restenosis after coronary angioplasty in unstable angina pectoris. American Journal of Cardiology, 1996, 77, 875-877.	1.6	19
242	Atherosclerotic Plaque Regression: Fact or Fiction?. Cardiovascular Drugs and Therapy, 2010, 24, 311-317.	2.6	19
243	Impaired renal function affects clinical outcomes and management of patients with heart failure. ESC Heart Failure, 2017, 4, 576-584.	3.1	19
244	â€~Primary' Microvascular Angina: Clinical Characteristics, Pathogenesis and Management. Interventional Cardiology Review, 2018, 13, 108.	1.6	19
245	Preangioplasty complicated coronary stenosis morphology as a predictor of restenosis. American Heart Journal, 1992, 123, 15-20.	2.7	18
246	Angiographic progression in patients with angina pectoris and normal or near normal coronary angiograms who are restudied due to unstable symptoms. European Heart Journal, 1998, 19, 1027-1033.	2.2	18
247	Endothelial dysfunction, subangiographic atheroma, and unstable symptoms in patients with chest pain and normal coronary arteriograms. Clinical Cardiology, 2000, 23, 645-652.	1.8	18
248	Cardiac Syndrome X: An Overview. Hospital Practice (1995), 2000, 35, 75-94.	1.0	18
249	Endothelin-Like Immunoreactivity in Atherosclerotic Human Coronary Arteries. Journal of Cardiovascular Pharmacology, 1995, 26, S442-444.	1.9	18
250	MINOCA presenting with STEMI: incidence, aetiology and outcome in a contemporaneous cohort. Journal of Thrombosis and Thrombolysis, 2019, 48, 533-538.	2.1	17
251	Clinical outcomes in patients with primary stable microvascular angina: is the jury still out?. European Heart Journal Quality of Care & Clinical Outcomes, 2019, 5, 283-291.	4.0	17
252	Serum adiponectin and cardiovascular risk in chronic kidney disease and kidney transplantation. Journal of Nephrology, 2010, 23, 77-84.	2.0	17

#	Article	IF	CITATIONS
253	Comparison between ventricular gradient and a new descriptor of the wavefront direction of ventricular activation and recovery. Clinical Cardiology, 2002, 25, 230-236.	1.8	16
254	Relation of ischemia-modified albumin levels and left ventricular systolic function in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Clinica Chimica Acta, 2008, 388, 196-199.	1.1	16
255	Usefulness of Intraplatelet Melatonin Levels to Predict Angiographic No-Reflow After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2010, 106, 1540-1544.	1.6	16
256	Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European Heart Journal, 2018, 39, 2274-2281.	2.2	16
257	Enhanced vasomotor responses of complex coronary stenoses to acetylcholine in stable angina peetoris. American Journal of Cardiology, 1995, 75, 725-728.	1.6	15
258	Neopterin—a forgotten biomarker. Journal of the American College of Cardiology, 2003, 42, 1142-1143.	2.8	15
259	Cholesterol composition of erythrocyte membranes and its association with clinical presentation of coronary artery disease. Coronary Artery Disease, 2008, 19, 583-590.	0.7	15
260	Acetylcholine-induced coronary spasm in patients with unobstructed coronary arteries is associated with elevated concentrations of soluble CD40 ligand and high-sensitivity C-reactive protein. Coronary Artery Disease, 2015, 26, 126-132.	0.7	15
261	Contrast agents for cardiovascular magnetic resonance imaging: an overview. Journal of Materials Chemistry B, 2017, 5, 5714-5725.	5.8	15
262	Assessing cardiovascular risk in chronic kidney disease patients prior to kidney transplantation: clinical usefulness of a standardised cardiovascular assessment protocol. BMC Nephrology, 2018, 19, 2.	1.8	15
263	Comparative effects of theophylline and isosorbide dinitrate on exercise capacity in stable angina pectoris, and their mechanisms of action. American Journal of Cardiology, 1989, 64, 1098-1102.	1.6	14
264	Progression of complex coronary artery stenosis in patients with angina pectoris. Coronary Artery Disease, 1992, 3, 305-312.	0.7	14
265	Ischemia-Modified Albumin: The Importance of Oxidative Stress. Journal of the American College of Cardiology, 2007, 49, 2375-2376.	2.8	14
266	Randomised, Double-Blind, Placebo-Controlled Trial of Ivabradine in Patients with Acute Coronary Syndrome: Effects of the I f Current Inhibitor Ivabradine on Reduction of Inflammation Markers in Patients with Acute Coronary Syndrome—RIVIERA Trial Study Design and Rationale. Cardiovascular Drugs and Therapy, 2009, 23, 243-247.	2.6	14
267	C-reactive protein predicts functional status and correlates with left ventricular ejection fraction in patients with chronic stable angina. Atherosclerosis, 2009, 205, 319-324.	0.8	14
268	Assessment of high onâ€treatment platelet reactivity in patients with ischemic heart disease: concordance between the Multiplate and VerifyNow assays. Journal of Thrombosis and Haemostasis, 2013, 11, 379-381.	3.8	14
269	Provocative tests for coronary artery spasm in MINOCA: necessary and safe?. European Heart Journal, 2018, 39, 99-101.	2.2	14
270	Total coronary occlusion in non ST elevation myocardial infarction: Time to change our practice?. International Journal of Cardiology, 2021, 329, 1-8.	1.7	14

#	Article	IF	CITATIONS
271	Effects of theophylline, atenolol and their combination on myocardial ischemia in stable angina pectoris. American Journal of Cardiology, 1990, 66, 1157-1162.	1.6	13
272	Recovery-phase patterns of ST segment depression in the heart rate domain cannot distinguish between anginal patients with coronary artery disease and patients with syndrome X. American Heart Journal, 1991, 122, 1593-1598.	2.7	13
273	Serum Endothelin Levels and Pain Perception in Patients With Cardiac Syndrome X and in Healthy Controls. American Journal of Cardiology, 1997, 80, 637-640.	1.6	13
274	Neopterin levels in patients with coronary artery disease are independent of chlamydia pneumoniae seropositivity. American Heart Journal, 2003, 146, 69-74.	2.7	13
275	Alteplase treatment affects circulating matrix metalloproteinase concentrations in patients with ST segment elevation acute myocardial infarction. Thrombosis Research, 2006, 118, 221-227.	1.7	13
276	Diurnal variation of circulating myeloperoxidase levels in patients with ST-segment elevation myocardial infarction. International Journal of Cardiology, 2010, 144, 407-409.	1.7	13
277	Elevated circulating soluble form of CD40 ligand in patients with cardiac syndrome X. Atherosclerosis, 2010, 213, 637-641.	0.8	13
278	Glycosylated apolipoprotein J in cardiac ischaemia: molecular processing and circulating levels in patients with acute ischaemic events. European Heart Journal, 2022, 43, 153-163.	2.2	13
279	Mechanisms of coronary artery spasm. Trends in Cardiovascular Medicine, 1991, 1, 289-294.	4.9	12
280	Coronary stenosis progression differs in patients with stable angina pectoris with and without a previous history of unstable angina. European Heart Journal, 1996, 17, 1488-1494.	2.2	12
281	Effect of magnesium sulphate in patients with unstable angina: A double blind, randomized, placebo-controlled study. European Heart Journal, 1997, 18, 1269-1277.	2.2	12
282	Neopterin predicts left ventricular remodeling in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Atherosclerosis, 2010, 211, 574-578.	0.8	12
283	Clinical scores and patient risk stratification in non-ST elevation acute coronary syndrome. International Journal of Cardiology, 2011, 146, 219-224.	1.7	12
284	Age Related Issues in Reperfusion of Myocardial Infarction. Cardiovascular Drugs and Therapy, 2011, 25, 139-148.	2.6	12
285	Release of platelet activation markers during coronary angioplasty. Coronary Artery Disease, 2000, 11, 391-398.	0.7	11
286	Placental infection with Chlamydia pneumoniae and intrauterine growth restriction. Cardiovascular Research, 2003, 60, 165-169.	3.8	11
287	Pregnancy-associated plasma protein-A and cardiovascular risk. European Heart Journal, 2006, 27, 1637-1639.	2.2	11
288	Psychological coping and recurrent major adverse cardiac events following acute coronary syndrome. British Journal of Psychiatry, 2015, 207, 256-261.	2.8	11

#	Article	IF	CITATIONS
289	Pregnancy-associated plasma protein a: Has this biomarker crossed the boundary from research to clinical practice?. Drug News and Perspectives, 2009, 22, 341.	1.5	11
290	Effects of diltiazem alone or with isosorbide dinitrate or with atenolol both acutely and chronically for stable angina pectoris. American Journal of Cardiology, 1989, 64, 717-724.	1.6	10
291	Serum sialic acid concentration is not associated with the extent or severity of coronary artery disease in patients with stable angina pectoris. American Heart Journal, 1998, 136, 620-623.	2.7	10
292	A protective contribution of the Q allele of the R353Q polymorphism of the Factor VII gene in individuals with chronic stable angina?. International Journal of Cardiology, 2005, 100, 395-399.	1.7	10
293	Medical Management of the Diabetic Patient with Coronary Artery Disease. Current Pharmaceutical Design, 2008, 14, 2527-2536.	1.9	10
294	Killer cell immunoglobulin receptor profile on <scp>CD</scp> 4 ⁺ Â <scp>CD</scp> 28 ^{â^'} T cells and their pathogenic role in nonâ€dialysisâ€dependent and dialysisâ€dependent chronic kidney disease patients. Immunology, 2015, 145, 105-113.	4.4	10
295	Role of ivabradine in management of stable angina in patients with different clinical profiles. Open Heart, 2018, 5, e000725.	2.3	10
296	Takotsubo syndrome's pathophysiology: still a mystery?. European Heart Journal, 2019, 40, 1989-1989.	2.2	10
297	Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 187-210.	3.0	10
298	Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 557-567.	3.0	10
299	Comment on Immunoassays Developed for Pregnancy-Associated Plasma Protein-A (PAPP-A) in Pregnancy May Not Recognize PAPP-A in Acute Coronary Syndromes. Clinical Chemistry, 2006, 52, 1619-1620.	3.2	9
300	Review: Adiponectin for prediction of cardiovascular risk?. British Journal of Diabetes and Vascular Disease, 2009, 9, 150-154.	0.6	9
301	C-reactive protein improves risk prediction in patients with acute coronary syndrome, or does it?. European Heart Journal, 2010, 31, 274-277.	2.2	9
302	A meta-analysis of published studies of endothelial dysfunction does not support its routine clinical use. International Journal of Clinical Practice, 2015, 69, 649-658.	1.7	9
303	Ischemic threshold varies in response to different types of exercise in patients with chronic stable angina. American Heart Journal, 1989, 118, 539-544.	2.7	8
304	Effects of beta2-adrenoceptor stimulation on exercise-induced myocardial ischemia. American Journal of Cardiology, 1991, 68, 111-114.	1.6	8
305	Angina pectoris with normal coronary arteriograms. Coronary Artery Disease, 1992, 3, 547-554.	0.7	8
306	Role of ischemia modified albumin to ST-segment resolution after mechanical reperfusion in patients with ST-segment elevation myocardial infarction. Atherosclerosis, 2009, 203, 576-580.	0.8	8

#	Article	IF	CITATIONS
307	Neopterin — Marker of coronary artery disease activity or extension in patients with chronic stable angina?. International Journal of Cardiology, 2010, 144, 74-75.	1.7	8
308	Ischaemic heart disease in the ageing woman. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2013, 27, 689-697.	2.8	8
309	The Interface of Therapeutics and Genomics in Cardiovascular Medicine. Cardiovascular Drugs and Therapy, 2021, 35, 663-676.	2.6	8
310	The association of air pollutants exposure with subclinical inflammation and carotid atherosclerosis. International Journal of Cardiology, 2021, 342, 108-114.	1.7	8
311	Creatine kinase MB isoforms: sensitive markers of ischemic myocardial damage. Clinical Chemistry, 1994, 40, 1265-71.	3.2	8
312	Inflammatory biomarkers of coronary atheromatous plaque vulnerability. Panminerva Medica, 2005, 47, 81-91.	0.8	8
313	Is Amiodarone an Ideal Antiarrhythmic Drug?. PACE - Pacing and Clinical Electrophysiology, 1984, 7, 272-275.	1.2	7
314	A combination of electrocardiographic methods represents a further step toward the noninvasive identification of patients with syndrome X. American Heart Journal, 1992, 123, 53-58.	2.7	7
315	Are polymorphisms in the ACE gene a potent genetic risk factor for restenosis?. Heart, 1994, 72, 101-101.	2.9	7
316	[¹²⁵ I]-ET=1 Binding to Perivascular Nerves of Human Epicardial Coronary Arteries. Endothelium: Journal of Endothelial Cell Research, 1996, 4, 231-234.	1.7	7
317	Heart rateâ€independent prolongation of QTc interval in women with syndrome X. Clinical Cardiology, 1997, 20, 357-360.	1.8	7
318	Complex stenosis morphology predicts late reocclusion during follow-up after myocardial infarction in patients with patent infarct–related coronary arteries. American Heart Journal, 1998, 136, 877-883.	2.7	7
319	"Normal―coronary arteriograms, "abnormal―haemodynamics. Lancet, The, 2002, 359, 1631-1632.	13.7	7
320	Secondary Prevention After Acute Myocardial Infarction and Coronary Revascularisation: Focus on Angiotensin Converting Enzyme Inhibitors. Cardiovascular Drugs and Therapy, 2008, 22, 185-191.	2.6	7
321	Beneficial effects of statin treatment after myocardial infarction: Is progenitor cell mobilization the missing link?. International Journal of Cardiology, 2008, 130, 301-303.	1.7	7
322	Assessment of Carotid Compliance Using Real Time Vascular Ultrasound Image Analysis in Marfan Syndrome. Echocardiography, 2009, 26, 441-451.	0.9	7
323	Addressing modifiable risk factors for coronary heart disease in primary care: an evidence-base lost in translation. Family Practice, 2010, 27, 370-378.	1.9	7
324	Myocardial stunning identified by using strain/strain rate imaging during dobutamine stress echocardiography in a rare late recurrence of Tako–Tsubo syndrome. International Journal of Cardiology, 2010, 145, e9-e12.	1.7	7

#	Article	IF	CITATIONS
325	Coronary artery spasm as a cause for myocardial infarction in patients with systemic inflammatory disease. International Journal of Cardiology, 2011, 151, e32-e34.	1.7	7
326	Cardiopulmonary exercise testing for the assessment of exercise capacity in patients with cardiac syndrome X. International Journal of Cardiology, 2012, 154, 85-87.	1.7	7
327	Cardiovascular pharmacotherapy in older people: challenges posed by cardiovascular drug prescription in the elderly. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 277-279.	3.0	7
328	Commentary - The ISCHEMIA trial. International Journal of Cardiology, 2020, 304, 1-4.	1.7	7
329	Acute exposure to diesel affects inflammation and vascular function. European Journal of Preventive Cardiology, 2021, 28, 1192-1200.	1.8	7
330	Chronic infections and coronary heart disease. International Journal of Clinical Practice, 1999, 53, 460-6.	1.7	7
331	Duration of ST segment depression after exercise-induced myocardial ischemia is influenced by body position during recovery but not by type of exercise. American Heart Journal, 1991, 121, 1665-1670.	2.7	6
332	Key references on coronary artery spasm Circulation, 1994, 89, 2442-2446.	1.6	6
333	"Syndrome X―as a consequence of acute myocardial infarction. American Journal of Cardiology, 1994, 74, 494-495.	1.6	6
334	Microvascular angina in patients with syndrome X. Clinical Research in Cardiology, 2000, 89, IX121-IX125.	1.1	6
335	Gender differences in the treatment of chronic ischemic heart disease: prognostic implications. Fundamental and Clinical Pharmacology, 2010, 24, 707-710.	1.9	6
336	Treatment strategies for chronic stable angina. Expert Opinion on Pharmacotherapy, 2011, 12, 2833-2844.	1.8	6
337	Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence. Expert Review of Cardiovascular Therapy, 2014, 12, 933-947.	1.5	6
338	Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention. International Journal of Cardiology, 2021, 337, 1-8.	1.7	6
339	International prospective cohort study of microvascular angina – Rationale and design. IJC Heart and Vasculature, 2020, 31, 100630.	1.1	6
340	The relationship between change and initial value: the continuing problem of regresion to the mean. European Heart Journal, 1995, 16, 289-289.	2.2	5
341	Silent myocardial ischaemia: clinical relevance and treatment. Expert Opinion on Investigational Drugs, 2005, 14, 423-434.	4.1	5
342	Papel de la neopterina en la medicina cardiovascular. Revista Espanola De Cardiologia, 2009, 62, 1341-1342.	1.2	5

#	Article	IF	CITATIONS
343	Corrected QT Interval: A Prognostic Marker in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome?. Trends in Cardiovascular Medicine, 2011, 21, 129-135.	4.9	5
344	Prevalence of the type 1 Brugada electrocardiogram in Caucasian patients with suspected coronary spasm. Europace, 2011, 13, 1625-1631.	1.7	5
345	Insulin in Acute Coronary Syndrome: a Narrative Review with Contemporary Perspectives. Cardiovascular Drugs and Therapy, 2016, 30, 493-504.	2.6	5
346	Factor V Leiden polymorphism (FV Q506) in patients with ischaemic heart disease, and in different populations groups. Journal of Human Hypertension, 1996, 10, 433-4.	2.2	5
347	Chronic infection and atherogenesis. European Heart Journal, 1998, 19, 366-7.	2.2	5
348	Phenotype-based management of coronary microvascular dysfunction. Journal of Nuclear Cardiology, 2022, 29, 3332-3340.	2.1	5
349	Coronary artery spasm. Coronary Artery Disease, 1990, 1, 660-667.	0.7	4
350	Cardiac imaging in syndrome X: the problem of 'reverse redistribution'. European Heart Journal, 1996, 17, 1459-1461.	2.2	4
351	Angiotensin-converting enzyme insertion/deletion polymorphism in angina pectoris with normal coronary arteriograms. American Journal of Cardiology, 1996, 77, 877-879.	1.6	4
352	Polymorphism in apolipoprotein(a) kringle IV 37 (Met/Thr): Frequency in a London population and its association with coronary artery disease. Clinical Cardiology, 1997, 20, 870-872.	1.8	4
353	A comparative study of eccentric and concentric coronary stenosis vasomotion in patients with prinzmetal's variant angina and patients with stable angina pectoris. Clinical Cardiology, 1998, 21, 643-648.	1.8	4
354	Angiotension-converting enzyme gene I/D polymorphism in patients with angina and normal coronary arteriograms. International Journal of Cardiology, 2005, 98, 339-340.	1.7	4
355	Usefulness of serum neopterin levels in acute decompensated heart failure to predict renal dysfunction. Biomarkers, 2012, 17, 134-139.	1.9	4
356	No additional value of conventional and high-sensitivity cardiac troponin over clinical scoring systems in the differential diagnosis of type 1 vs. type 2 myocardial infarction. Clinical Chemistry and Laboratory Medicine, 2018, 56, 857-864.	2.3	4
357	Cardiovascular pharmacotherapy: a new ESC Handbook comprehensively addresses pharmacological treatment issues for patients with cardiovascular disease. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 185-186.	3.0	4
358	The management of stress hyperglycaemia in patients experiencing acute coronary syndrome: a topic worth revisiting. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 126-127.	3.0	4
359	Inferior ST-Elevation Myocardial Infarction Presenting When Urgent Primary Percutaneous Coronary Intervention Is Unavailable: Should We Adhere to Current Guidelines?. Cardiovascular Drugs and Therapy, 2020, 34, 865-870.	2.6	4
360	Testing for Coronary Artery SpasmÂNoninvasively. JACC: Cardiovascular Imaging, 2020, 13, 1888-1890.	5.3	4

#	Article	IF	CITATIONS
361	Finding acute coronary syndrome with serial troponin testing for rapid assessment of cardiac ischemic symptoms (FAST-TRAC): a study protocol. Clinical and Experimental Emergency Medicine, 2022, 9, 140-145.	1.6	4
362	Electrocardiographic Diagnosis of Transient Myocardial Ischemia Annals of the New York Academy of Sciences, 1990, 601, 51-60.	3.8	3
363	Effects of oxyfedrine on regional myocardial blood flow in patients with coronary artery disease. Cardiovascular Drugs and Therapy, 1991, 5, 991-996.	2.6	3
364	Local cytokine production and acute coronary events. International Journal of Cardiology, 2000, 73, 79-81.	1.7	3
365	Comparison of mid-term outcome in patients with three-vessel and/or left main disease undergoing percutaneous coronary intervention and coronary artery bypass graft surgery. European Journal of Cardio-thoracic Surgery, 2010, 37, 905-911.	1.4	3
366	Introduction. Cardiovascular Drugs and Therapy, 2016, 30, 339-340.	2.6	3
367	Myocardial blood flow reserve is impaired in patients with aortic valve calcification and unobstructed epicardial coronary arteries. International Journal of Cardiology, 2017, 248, 427-432.	1.7	3
368	Facile, productive, and cost-effective synthesis of a novel tetrazine-based iron oxide nanoparticle for targeted image contrast agents and nanomedicines. Journal of Nanoparticle Research, 2018, 20, 1.	1.9	3
369	Echocardiographic abnormalities in patients on kidney transplant waiting list. Journal of Nephrology, 2012, 25, 1119-1125.	2.0	3
370	Myocardial ischaemia in the hypertensive patientthe role of coronary microcirculation abnormalities. European Heart Journal, 1993, 14 Suppl J, 32-7.	2.2	3
371	Rapid coronary artery disease progression and angiographic stenosis morphology. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2000, 1, 21-5.	0.1	3
372	Detection of <i>Chlamydia pneumoniae</i> in atherosclerotic tissue: a comparative study of PCR and immunocytochemistry. British Journal of Biomedical Science, 2005, 62, 155-160.	1.3	2
373	Flow-Mediated Dilation: Just a Marker of Local Shear Stress?. Hypertension, 2005, 45, e11-2; author reply e11-2.	2.7	2
374	Markers of myocardial ischaemia. European Heart Journal, 2006, 27, 758-758.	2.2	2
375	Neopterin and coronary artery disease. Journal of Cardiology, 2009, 54, 344-345.	1.9	2
376	STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone). Journal of the American College of Cardiology, 2009, 53, 2036-2038.	2.8	2
377	Role of Neopterin in Cardiovascular Medicine. Revista Espanola De Cardiologia (English Ed), 2009, 62, 1341-1342.	0.6	2
378	Papel de la microcirculación coronaria en las enfermedades cardiacas. Cardiocore, 2011, 46, 161-166.	0.0	2

#	Article	IF	CITATIONS
379	Molecular imaging of inflammation for detection of vulnerable atheromatous plaques. European Heart Journal, 2012, 33, 1857-1860.	2.2	2
380	Enfermedad cardiovascular en el anciano: comentario. Revista Espanola De Cardiologia, 2012, 65, 196.	1.2	2
381	Clinical Trials Update Esc Congress 2011. Cardiovascular Drugs and Therapy, 2012, 26, 77-84.	2.6	2
382	Response to letter from Picichè: The microvascular network connecting extracardiac arteries to the heart. International Journal of Cardiology, 2018, 259, 56.	1.7	2
383	Coronary Artery Spasm and Flow‣imiting Coronary Stenoses: A Malevolent Duo?. Journal of the American Heart Association, 2021, 10, e019679.	3.7	2
384	Patterns of coronary artery stenosis vasomotion: observed versus "predicted" stenosis reactivity in patients with chronic stable angina. Coronary Artery Disease, 1993, 4, 529-36.	0.7	2
385	Increased neopterin in patients with chronic and acute coronary syndromes. Journal of the American College of Cardiology, 1998, 31, 1215-6.	2.8	2
386	Aggressive pattern of angina after successful coronary angioplasty: the role of clinical and angiographic factors. European Heart Journal, 1995, 16, 1085-1091.	2.2	1
387	Treatment of stable angina pectoris: is there a role for dipyridamole?. European Heart Journal, 2001, 22, 1762-1764.	2.2	1
388	Cardiac troponin release in response to transient ST segment depression. International Journal of Cardiology, 2002, 85, 252-253.	1.7	1
389	Prediction of infarction-related artery occlusion and multivessel disease in postinfarction angina. International Journal of Cardiology, 2007, 115, 381-385.	1.7	1
390	Estudios de polimorfismos genéticos e infarto de miocardio: ¿una especie en vÃas de extinción?. Revista Espanola De Cardiologia, 2009, 62, 347-349.	1.2	1
391	New Challenges Ahead for the Newer Oral Thrombin Inhibitors that Aim at Replacing Warfarin in Clinical Practice—Any Role for Scientific Societies in the Debate?. Cardiovascular Drugs and Therapy, 2012, 26, 359-360.	2.6	1
392	Response to Letters Regarding Article, "Clinical Usefulness, Angiographic Characteristics, and Safety Evaluation of Intracoronary Acetylcholine Provocation Testing Among 921 Consecutive White Patients With Unobstructed Coronary Arteries― Circulation, 2015, 131, e325.	1.6	1
393	Stable Angina Pectoris: Definition, Clinical Presentation and Pathophysiologic Mechanisms. , 2016, , 15-35.		1
394	Neopterin for prediction of inâ€hospital atrial fibrillation – the â€~forgotten biomarker' strikes again. Journal of Internal Medicine, 2018, 283, 591-593.	6.0	1
395	An improved synthesis of a cyclopropene-based molecule for the fabrication of bioengineered tissues via copper-free click chemistry. Journal of Applied Biomaterials and Functional Materials, 2019, 17, 228080001984474.	1.6	1
396	The ISCHEMIA Trial: And the Winner Isâ \in \mid the Patient. European Cardiology Review, 2021, 16, e10.	2.2	1

#	Article	IF	CITATIONS
397	[3H]Bosentan Binding to Human Coronary Artery. Journal of Cardiovascular Pharmacology, 1995, 26, S376-379.	1.9	1
398	Efficacy of Carvedilol in Exercise-Induced Myocardial Ischemia. Journal of Cardiovascular Pharmacology, 1987, 10, S137-S140.	1.9	1
399	Efficacy of amiodarone in patients with Chagas' disease and life-threatening arrhythmias. British Journal of Clinical Practice Supplement, 1986, 44, 11-5.	0.1	1
400	Coronary artery stenosis morphology and degree of vasomotion in patients with Prinzmetal's variant angina. Journal of the American College of Cardiology, 1996, 27, 107.	2.8	0
401	Working Group on Microcirculation. European Heart Journal, 1996, 17, 1917-1918.	2.2	Ο
402	Elevated Chlamydia pneumoniae Antibodies, Cardiovascular Events, and Azithromycin in Male Survivors of Myocardial Infarction. Infectious Diseases in Clinical Practice, 1998, 7, 220.	0.3	0
403	The Management of Chronic Ischemic Heart Disease in the Elderly. The American Journal of Geriatric Cardiology, 2000, 9, 145-151.	0.6	Ο
404	Serum markers of inflammation and cardiovascular risk. , 2002, , 345-354.		0
405	The Author???s Reply. American Journal of Cardiovascular Drugs, 2004, 4, 423.	2.2	Ο
406	Multiple complex stenoses and chronic stable angina pectoris. International Journal of Cardiology, 2005, 102, 549-550.	1.7	0
407	Marcadores inmunológicos en la enfermedad coronaria. Cardiocore, 2010, 45, 18-21.	0.0	Ο
408	President's Page. Cardiovascular Drugs and Therapy, 2011, 25, 107-107.	2.6	0
409	Pharmacotherapy Crisis in the Spotlight—Is Open Collaboration Between Academia and Industry the Answer?. Cardiovascular Drugs and Therapy, 2011, 25, 187-188.	2.6	Ο
410	The Difficult Task of Teaching Cardiovascular Pharmacotherapy. Cardiovascular Drugs and Therapy, 2011, 25, 363-364.	2.6	0
411	High Dose Statin Treatment and New Onset Diabetes. Cardiovascular Drugs and Therapy, 2011, 25, 571-572.	2.6	Ο
412	PERTINENT (a substudy of the EUROPA trial): a persistent legacy: EXPERTS' PERSPECTIVE. Cardiovascular Research, 2012, 96, 202-203.	3.8	0
413	HDL- Cholesterol: A Nut Too Hard to Crack?. Cardiovascular Drugs and Therapy, 2012, 26, 433-434.	2.6	0
414	Cardiovascular Disease in the Elderly: Comment. Revista Espanola De Cardiologia (English Ed), 2012, 65, 196.	0.6	0

#	Article	IF	CITATIONS
415	Statin Treatment for All Individuals With Cholesterol Concentrations Above "Target�. Cardiovascular Drugs and Therapy, 2012, 26, 189-190.	2.6	0
416	Cardiovascular Pharmacotherapy can Reduce Mortality. Cardiovascular Drugs and Therapy, 2012, 26, 85-86.	2.6	0
417	Coronary Microcirculation: A Clinical Perspective. , 2015, , 639-654.		0
418	Reply to the letter from He et al. Is NPY causing myocardial ischemia in patients with microvascular angina associated with its abnormal constrictor response at the microcirculation level?. International Journal of Cardiology, 2017, 247, 53.	1.7	0
419	Vitamin D deficiency, endothelial function and bone biomarkers in post-kidney transplantation patients from North India. International Urology and Nephrology, 2019, 51, 181-186.	1.4	0
420	The new <i>European Heart Journal</i> Ischaemic Heart Disease Team. European Heart Journal, 2020, 41, 3503-3503.	2.2	0
421	Response to "Should Target Glycemic Range Be Exactly the Same for Patients With Acute Myocardial Infarction Versus Without Diabetes?― Journal of Emergency Medicine, 2020, 59, 311-312.	0.7	0
422	Letter by Consuegra-Sánchez et al Regarding Article, "Magnesium-Based Resorbable Scaffold Versus Permanent Metallic Sirolimus-Eluting Stent in Patients With ST-Segment Elevation Myocardial Infarction: The MAGSTEMI Randomized Clinical Trial― Circulation, 2020, 141, e746-e747.	1.6	0
423	Editorial: The EXCEL Trial. European Cardiology Review, 2021, 16, e09.	2.2	0
424	Non ST-elevation myocardial infarction (NSTEMI) patients with total coronary artery occlusion: More than meets the eye. International Journal of Cardiology, 2021, 333, 52.	1.7	0
425	Foreword. European Cardiology Review, 2014, 9, 64.	2.2	0
426	Microcirculation-Coronary: A Clinical Perspective. , 2014, , 1-17.		0
427	An Overview of Treatment and Guidelines: ESC/ACC-AHA/NICE. , 2015, , 33-56.		0
428	Foreword. European Cardiology Review, 2015, 10, 5.	2.2	0
429	Foreword. European Cardiology Review, 2015, 10, 73.	2.2	0
430	European Cardiology Review partners with the International Society of Cardiovascular Pharmacotherapy. European Cardiology Review, 2016, 11, 7.	2.2	0
431	European Cardiology Review partners with the International Society of Cardiovascular Pharmacotherapy. European Cardiology Review, 2016, 11, 114.	2.2	0
432	Foreword. European Cardiology Review, 2016, 11, 5.	2.2	0

#	ARTICLE	IF	CITATIONS
433	Foreword. European Cardiology Review, 2016, 11, 68.	2.2	0
434	Microvascular Angina: Diagnosis, Prognosis and Treatment. , 2016, , 65-93.		0
435	Management of Angina. , 2016, , 111-163.		Ο
436	Foreword. European Cardiology Review, 2017, 12, 75.	2.2	0
437	Noise Pollution and Arterial Hypertension: Can we Remain Mute Anymore?. European Cardiology Review, 2017, 12, 24.	2.2	0
438	Foreword. European Cardiology Review, 2017, 12, 6.	2.2	0
439	Foreword. European Cardiology Review, 2018, 13, 90.	2.2	Ο
440	Foreword. European Cardiology Review, 2018, 13, 5.	2.2	0
441	Foreword. European Cardiology Review, 2019, 14, 76-76.	2.2	Ο
442	Foreword. European Cardiology Review, 2019, 14, 138-138.	2.2	0
443	'Comments on circulating transforming growth factor beta 1 and coronary artery disease'. Cardiovascular Research, 1998, 37, 829-30.	3.8	Ο
444	Ethnic and Regional Differences in the Management of Angina: The Way Forward. European Cardiology Review, 2022, 17, e07.	2.2	0
445	Regional Variations in ETA/ETB Binding Sites in Human Coronary Vasculature. Journal of Cardiovascular Pharmacology, 1995, 26, S351-354.	1.9	0